Tower Research Capital LLC (Trc) Aligos Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 46,476 shares of ALGS stock, worth $381,103. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,476
Previous 8,022
479.36%
Holding current value
$381,103
Previous $7,000
128.57%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ALGS
# of Institutions
52Shares Held
47.3MCall Options Held
1.4KPut Options Held
300-
Armistice Capital, LLC New York, NY7.26MShares$59.5 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$52.4 Million0.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$50 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5MShares$41 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$29.1 Million0.18% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $326M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...